Tvardi Therapeutics Inc (TVRD)

$4.63 +0.07 (1.54%)
Market Cap 42.12M
Revenue (ttm) 7.14M
Net Income (ttm) -70.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -992.58%
Debt to Equity Ratio 0.00
Volume 68,906
Avg Vol 144,364
Day's Range N/A - N/A
Shares Out 9.38M
Stochastic %K 78%
Beta 0.09
Analysts Sell
Price Target $9.20

Company Profile

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 489 8654
Address:
3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, United States
sellhigh69
sellhigh69 Jan. 14 at 4:39 PM
$TVRD https://www.biospace.com/press-releases/tvardi-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 🙏👍
0 · Reply
Estimize
Estimize Jan. 14 at 2:12 PM
Wall St is expecting -0.65 EPS for $TVRD Q4 [Reporting 04/01 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
cubie
cubie Jan. 12 at 10:24 PM
$TVTX $RZLT $OTLK $KALA $TVRD cubie teaches
0 · Reply
sellhigh69
sellhigh69 Jan. 9 at 4:06 PM
$TVRD https://www.biospace.com/press-releases/tvardi-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference GIDDY UP
0 · Reply
sellhigh69
sellhigh69 Jan. 8 at 7:30 PM
$TVRD https://www.manilatimes.net/2026/01/08/tmt-newswire/globenewswire/tvardi-therapeutics-announces-further-phase-2-revert-ipf-data-expanding-clinical-insights/2255403
0 · Reply
Estimize
Estimize Jan. 1 at 9:00 PM
Wall St is expecting -0.65 EPS for $TVRD Q4 [Reporting 04/01 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
sellhigh69
sellhigh69 Dec. 31 at 8:36 PM
$TVRD looking good.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 30 at 11:25 PM
$TVRD Current Stock Price: $4.23 Contracts to trade: $5 TVRD Jan 16 2026 Call Entry: $0.10 Exit: $0.19 ROI: 91% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 9:51 PM
$TVRD Share Price: $4.23 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $0.26 – $0.32 Target Zone: $0.43 – $0.53 Potential Upside: 60% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Dec. 26 at 8:50 PM
$UAA $UA interesting one for Monday $AIV $TVRD $AGPU degen plays
1 · Reply
Latest News on TVRD
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:05 PM EST - 6 days ago

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Dec 24, 2025, 11:23 AM EST - 21 days ago

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Dec 23, 2025, 10:18 AM EST - 22 days ago

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Dec 20, 2025, 8:01 AM EST - 25 days ago

SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Dec 4, 2025, 10:28 AM EST - 5 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 2 months ago

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 2 months ago

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Nov 12, 2025, 10:10 AM EST - 2 months ago

TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Nov 9, 2025, 9:18 AM EST - 2 months ago

TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 2 months ago

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Oct 15, 2025, 10:02 AM EDT - 3 months ago

TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Oct 13, 2025, 2:23 PM EDT - 3 months ago

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge

Oct 13, 2025, 1:12 PM EDT - 3 months ago

Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge

AAAU DGP GLD GLDM IAU OUNZ

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Oct 13, 2025, 7:30 AM EDT - 3 months ago

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 21, 2025, 8:00 AM EDT - 5 months ago

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Aug 14, 2025, 4:01 PM EDT - 5 months ago

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:00 AM EDT - 6 months ago

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Jun 12, 2025, 3:07 PM EDT - 7 months ago

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025, 8:00 AM EDT - 8 months ago

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

May 20, 2025, 8:00 AM EDT - 8 months ago

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 8 months ago

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

May 6, 2025, 7:00 AM EDT - 9 months ago

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Apr 15, 2025, 4:05 PM EDT - 9 months ago

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

CARA

sellhigh69
sellhigh69 Jan. 14 at 4:39 PM
$TVRD https://www.biospace.com/press-releases/tvardi-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 🙏👍
0 · Reply
Estimize
Estimize Jan. 14 at 2:12 PM
Wall St is expecting -0.65 EPS for $TVRD Q4 [Reporting 04/01 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
cubie
cubie Jan. 12 at 10:24 PM
$TVTX $RZLT $OTLK $KALA $TVRD cubie teaches
0 · Reply
sellhigh69
sellhigh69 Jan. 9 at 4:06 PM
$TVRD https://www.biospace.com/press-releases/tvardi-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference GIDDY UP
0 · Reply
sellhigh69
sellhigh69 Jan. 8 at 7:30 PM
$TVRD https://www.manilatimes.net/2026/01/08/tmt-newswire/globenewswire/tvardi-therapeutics-announces-further-phase-2-revert-ipf-data-expanding-clinical-insights/2255403
0 · Reply
Estimize
Estimize Jan. 1 at 9:00 PM
Wall St is expecting -0.65 EPS for $TVRD Q4 [Reporting 04/01 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
sellhigh69
sellhigh69 Dec. 31 at 8:36 PM
$TVRD looking good.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 30 at 11:25 PM
$TVRD Current Stock Price: $4.23 Contracts to trade: $5 TVRD Jan 16 2026 Call Entry: $0.10 Exit: $0.19 ROI: 91% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 9:51 PM
$TVRD Share Price: $4.23 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $0.26 – $0.32 Target Zone: $0.43 – $0.53 Potential Upside: 60% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Dec. 26 at 8:50 PM
$UAA $UA interesting one for Monday $AIV $TVRD $AGPU degen plays
1 · Reply
kshonstocks
kshonstocks Dec. 26 at 8:49 PM
starting some $TVRD for a bounce/january play
0 · Reply
kshonstocks
kshonstocks Dec. 26 at 7:44 PM
$TVRD hod off a base
0 · Reply
EchelonExpert
EchelonExpert Dec. 26 at 9:07 AM
$TVRD This name increasingly trades on execution rhythm rather than speculation about possibilities. Cash generation will determine how self-sustaining growth becomes. Operational wins could gradually shift expectations upward. Proof, rather than potential, becomes the key differentiator.
0 · Reply
CruxCore
CruxCore Dec. 26 at 4:29 AM
$TVRD Investors are recalibrating expectations as the balance shifts from vision to execution. The business must show that scaling does not introduce uncontrolled risk. Consistent milestones could shift perception faster than fundamentals alone. The thesis improves only as operational proof accumulates.
0 · Reply
Fakhrul123
Fakhrul123 Dec. 15 at 1:29 PM
$TVRD
0 · Reply
VincM
VincM Dec. 11 at 3:12 PM
$TVRD 👀
0 · Reply
sellhigh69
sellhigh69 Dec. 9 at 12:48 PM
$TVRD do they have any drugs in a pipeline thanks
1 · Reply
tagajutah
tagajutah Dec. 8 at 6:14 PM
$TVRD bought 1000 at 4,08. Just a gamble.
0 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 4 at 9:59 PM
$GRI no matter the bear thesis IM STILL GAMBLING ON iPf DATA. I know what the market prices it at. Look at $PLRX $TVRD $ARCT
2 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 4 at 8:21 PM
$GRI iPf Data worth at Least 300 million market cap Ask $PLRX lost 900 million market cap $TVRD lost over 300 million market cap $ARCT with a 6 person trial Lost 300 million market cap $GRI bio market cap 6.4 million market U do the math on a 300 million market cap boost
1 · Reply
MIT_P983
MIT_P983 Dec. 3 at 8:22 PM
$GRI $PLRX $TVRD $ARCT
0 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 3 at 8:20 PM
$GRI $0 or. $300 million market cap on Data $PLRX lost 900 million market cap $TVRD lost 300 million market cap $ARCT lost 300 million market cap This trend leads me to believe iPf data is worth 300 million market cap
0 · Reply